InflaRx N.V. reported its financial results for the three months ended March 31, 2025, showing no revenues from GOHIBIC product sales for the quarter, a decrease of €36 thousand compared to Q1 2024. The company's net loss for the first quarter of 2025 narrowed to €8.3 million, or €0.13 per ordinary share, compared to €9.7 million, or €0.17 per ordinary share, in Q1 2024.
Research and development expenses decreased by €0.3 million to €7.0 million, primarily due to lower third-party expenses for INF904 development. General and administrative expenses increased by €1.5 million, mainly due to higher legal, consulting, and audit expenses, as well as higher personnel expenses related to share-based payments and the recent public offering.
As of March 31, 2025, InflaRx's total available funds amounted to approximately €65.7 million, including €47.3 million in cash and cash equivalents and €18.4 million in marketable securities. This strong financial position, bolstered by the February 2025 public offering that raised €28.7 million ($30.0 million) in gross proceeds, is expected to provide a cash runway into 2027.
The company anticipates the interim analysis for the vilobelimab Phase 3 trial in pyoderma gangrenosum (PG) by the end of May to early June 2025. Topline Phase 2a data for INF904 in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) are expected in summer 2025. InflaRx also completed sub-chronic and chronic toxicology studies for INF904 with no safety signals identified.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.